CBD as an Anti-Cancer Agent

Cannabidiol inhibits angiogenesis by multiple mechanisms.

Posted by Joe Pavlik on

Published: Br J Pharmacol. 2012 Nov;167(6):1218-31. doi: 10.1111/j.1476-5381.2012.02050.x. Cannabidiol inhibits angiogenesis by multiple mechanisms. Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V, Valenti M, Vicentini LM, Noonan DM, Albini A, Parolaro D. Abstract BACKGROUND AND PURPOSE: Several studies have demonstrated anti-proliferative and pro-apoptotic actions of cannabinoids on various tumours, together with their anti-angiogenic properties. The non-psychoactive cannabinoid cannabidiol (CBD) effectively inhibits the growth of different types of tumours in vitro and in vivo and down-regulates some pro-angiogenic signals produced by glioma cells. As its anti-angiogenic properties have not been thoroughly investigated to date, and...

Read more →

The use of cannabinoids as anticancer agents

Posted by Joe Pavlik on

Published: Volume 64, 4 January 2016, Pages 259–266 Progress in Neuro-Psychopharmacology and Biological Psychiatry The use of cannabinoids as anticancer agents Guillermo Velasco, Sonia Hernández-Tiedra, David Dávila, Mar Lorente Abstract It is well-established that cannabinoids exert palliative effects on some cancer-associated symptoms. In addition, evidences obtained during the last fifteen years support that these compounds can reduce tumor growth in animal models of cancer. Cannabinoids have been shown to activate an ER-stress related pathway that leads to the stimulation of autophagy- mediated cancer cell death. In addition, cannabinoids inhibit tumor angiogenesis and decrease cancer cell migration. The mechanisms of resistance...

Read more →

Cannabinoids as therapeutic agents in cancer: current status and future implications

Posted by Joe Pavlik on

Published: Oncotarget. 2014 Aug; 5(15): 5852–5872. Cannabinoids as therapeutic agents in cancer: current status and future implications Bandana Chakravarti, Janani Ravi, and Ramesh K. Ganju Abstract The pharmacological importance of cannabinoids has been in study for several years. Cannabinoids comprise of (a) the active compounds of the Cannabis sativa plant, (b) endogenous as well as (c) synthetic cannabinoids. Though cannabinoids are clinically used for anti-palliative effects, recent studies open a promising possibility as anti-cancer agents. They have been shown to possess anti-proliferative and anti-angiogenic effects in vitro as well as in vivo in different cancer models. Cannabinoids regulate key cell...

Read more →

Endocannabinoids as Guardians of Metastasis

Posted by Joe Pavlik on

Published: Int J Mol Sci. 2016 Feb; 17(2): 230. Endocannabinoids as Guardians of Metastasis Irmgard Tegeder, Xiaofeng Jia, Academic Editor Abstract Endocannabinoids including anandamide and 2-arachidonoylglycerol are involved in cancer pathophysiology in several ways, including tumor growth and progression, peritumoral inflammation, nausea and cancer pain. Recently we showed that the endocannabinoid profiles are deranged during cancer to an extent that this manifests in alterations of plasma endocannabinoids in cancer patients, which was mimicked by similar changes in rodent models of local and metastatic cancer. The present topical review summarizes the complexity of endocannabinoid signaling in the context of tumor growth...

Read more →

Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

Posted by Joe Pavlik on

Published: Biochem Pharmacol. 2014 Nov 15;92(2):312-25. doi: 10.1016/j.bcp.2014.07.014. Epub 2014 Jul 25. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B. Abstract Cannabinoids have been shown to promote the expression of the intercellular adhesion molecule 1 (ICAM-1) on lung cancer cells as part of their anti-invasive and antimetastatic action. Using lung cancer cell lines (A549, H460) and metastatic cells derived from a lung cancer patient, the present study addressed the impact of cannabinoid-induced ICAM-1 on cancer cell adhesion to lymphokine-activated killer (LAK) cells and LAK...

Read more →